全文获取类型
收费全文 | 161066篇 |
免费 | 10710篇 |
国内免费 | 1221篇 |
专业分类
耳鼻咽喉 | 2255篇 |
儿科学 | 3023篇 |
妇产科学 | 3742篇 |
基础医学 | 24041篇 |
口腔科学 | 3345篇 |
临床医学 | 15233篇 |
内科学 | 30772篇 |
皮肤病学 | 4345篇 |
神经病学 | 12046篇 |
特种医学 | 8114篇 |
外科学 | 21890篇 |
综合类 | 2170篇 |
现状与发展 | 5篇 |
一般理论 | 81篇 |
预防医学 | 9721篇 |
眼科学 | 4307篇 |
药学 | 13641篇 |
中国医学 | 1597篇 |
肿瘤学 | 12669篇 |
出版年
2023年 | 985篇 |
2022年 | 2739篇 |
2021年 | 4825篇 |
2020年 | 2465篇 |
2019年 | 3586篇 |
2018年 | 4402篇 |
2017年 | 3231篇 |
2016年 | 4188篇 |
2015年 | 5635篇 |
2014年 | 6908篇 |
2013年 | 8371篇 |
2012年 | 12646篇 |
2011年 | 12279篇 |
2010年 | 7252篇 |
2009年 | 6067篇 |
2008年 | 9254篇 |
2007年 | 9120篇 |
2006年 | 8377篇 |
2005年 | 7982篇 |
2004年 | 7120篇 |
2003年 | 6187篇 |
2002年 | 5373篇 |
2001年 | 4380篇 |
2000年 | 4029篇 |
1999年 | 3263篇 |
1998年 | 1315篇 |
1997年 | 1000篇 |
1996年 | 958篇 |
1995年 | 870篇 |
1994年 | 756篇 |
1993年 | 645篇 |
1992年 | 1576篇 |
1991年 | 1569篇 |
1990年 | 1354篇 |
1989年 | 1237篇 |
1988年 | 1156篇 |
1987年 | 1031篇 |
1986年 | 1010篇 |
1985年 | 885篇 |
1984年 | 645篇 |
1983年 | 563篇 |
1982年 | 400篇 |
1981年 | 377篇 |
1980年 | 338篇 |
1979年 | 520篇 |
1978年 | 406篇 |
1977年 | 393篇 |
1976年 | 344篇 |
1974年 | 358篇 |
1973年 | 327篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
Hyo-Kon Kim Sung-Han Ha Gi-Jun Lee Sun-O Yu Jung-Rae Kim 《Clinics in Orthopedic Surgery》2015,7(3):414-417
Synovial chondromatosis is a rare lesion in the wrist, but some cases in the distal radioulnar joint have been reported and previous case reports emphasize joint calcifications, shown on preoperative plain radiographs. We report an extremely uncommon case of synovial chondromatosis in the pisotriquetral joint, in which radiographs and magnetic resonance imaging did not demonstrate apparent calcified bodies. In our case, for the accurate diagnosis and treatment, surgical exploration of the joint and synovectomy with removal of loose bodies was performed. 相似文献
22.
23.
24.
JeongYun Choi Haeseung Lee EunJi Kwon HyeonJoon Kong OkSeon Kwon HyukJin Cha 《Molecular oncology》2021,15(2):679
The acquisition of chemoresistance remains a major cause of cancer mortality due to the limited accessibility of targeted or immune therapies. However, given that severe alterations of molecular features during epithelial‐to‐mesenchymal transition (EMT) lead to acquired chemoresistance, emerging studies have focused on identifying targetable drivers associated with acquired chemoresistance. Particularly, AXL, a key receptor tyrosine kinase that confers resistance against targets and chemotherapeutics, is highly expressed in mesenchymal cancer cells. However, the underlying mechanism of AXL induction in mesenchymal cancer cells is poorly understood. Our study revealed that the YAP signature, which was highly enriched in mesenchymal‐type lung cancer, was closely correlated to AXL expression in 181 lung cancer cell lines. Moreover, using isogenic lung cancer cell pairs, we also found that doxorubicin treatment induced YAP nuclear translocation in mesenchymal‐type lung cancer cells to induce AXL expression. Additionally, the concurrent activation of TGFβ signaling coordinated YAP‐dependent AXL expression through SMAD4. These data suggest that crosstalk between YAP and the TGFβ/SMAD axis upon treatment with chemotherapeutics might be a promising target to improve chemosensitivity in mesenchymal‐type lung cancer.
Abbreviations
- AUC
- area under the curve
- AXL
- AXL receptor tyrosine kinase
- BCL2
- B‐cell lymphoma 2
- CTD2
- cancer target discovery and development
- CTGF
- connective tissue growth factor
- DEG
- differentially expressed genes
- DOXO
- doxorubicin
- EMT
- epithelial–mesenchymal transition
- Eto
- etoposide
- FDA
- Food and Drug Administration
- ITGB3
- integrin beta‐3
- MAPK
- mitogen‐activated protein kinase
- MMP2
- matrix metalloproteinase‐2
- MMP9
- matrix metalloproteinase‐9
- mRNA
- messenger RNA
- NF‐κB
- nuclear factor kappa‐light‐chain‐enhancer of activated B cells
- SBE
- SMAD binding element
- SERPINE1
- serpin family E member 1
- siRNA
- small interfering RNA
- ssGSEA
- single‐sample gene set enrichment analysis
- TCGA
- The Cancer Genome Atlas
- TGFβ
- transforming growth factor beta
- YAP
- Yes‐associated protein
- YAP8SA
- mutants of inhibitory phosphorylation site at eight serine to Alanine of YAP
- ZEB1
- zinc finger E‐box binding homeobox 1
- ZEB2
- zinc finger E‐box‐binding homeobox 2
25.
26.
27.
28.
Harit Kapoor Kush Raj Lohani Tommy H. Lee Devendra K. Agrawal Sumeet K. Mittal 《CTS Clinical and Translational Science》2015,8(6):841-847
Esophageal adenocarcinoma is the fastest rising cancer in the United States. It develops from long‐standing gastroesophageal reflux disease which affects >20% of the general population. It carries a very poor prognosis with 5‐year survival <20%. The disease is known to sequentially progress from reflux esophagitis to a metaplastic precursor, Barrett''s esophagus and then onto dysplasia and esophageal adenocarcinoma. However, only few patients with reflux develop Barrett''s esophagus and only a minority of these turn malignant. The reason for this heterogeneity in clinical progression is unknown. To improve patient management, molecular changes which facilitate disease progression must be identified. Animal models can provide a comprehensive functional and anatomic platform for such a study. Rats and mice have been the most widely studied but disease homology with humans has been questioned. No animal model naturally simulates the inflammation to adenocarcinoma progression as in humans, with all models requiring surgical bypass or destruction of existing antireflux mechanisms. Valuable properties of individual models could be utilized to holistically evaluate disease progression. In this review paper, we critically examined the current animal models of Barrett''s esophagus, their differences and homologies with human disease and how they have shaped our current understanding of Barrett''s carcinogenesis. 相似文献
29.
Chih-Wei Hsu Sheng-Yu Lee Yao-Hsu Yang Liang-Jen Wang 《The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)》2020,23(10):653
BackgroundGeneric antidepressants are approved on the market based on evidence of bioequivalence to their brand-name versions. We aimed to assess whether generic antidepressants exert equal effectiveness as their brand-name counterparts for treating patients with depressive disorders.MethodsIn a nationwide, population-based cohort in Taiwan from 1997 through 2013, patients with a diagnosis of a depressive disorder aged between 18 and 65 years who were new users of antidepressant drugs were classified into either the brand-name group or the generic group. All patients were followed up until medication discontinuation or the end of the study period. We assessed the risk for hospitalization as a primary outcome and augmentation therapy, daily dose, medication discontinuation, or switching to another antidepressant as secondary outcomes.ResultsA total of 277 651 brand-name users (35.8% male; mean age: 41.2 years) and 270 583 generic users (35.8% male; mean age: 41.0 years) were divided into 10 different antidepressant groups (fluoxetine, sertraline, paroxetine, escitalopram, citalopram, venlafaxine, mirtazapine, moclobemide, imipramine, and bupropion). We found that patients treated with the generic form of sertraline, paroxetine, escitalopram, venlafaxine, mirtazapine, and bupropion demonstrated significantly higher risks of psychiatric hospitalization (adjusted hazard ratios ranged from 1.20–2.34), compared to their brand-name counterparts. The differences between brand-name antidepressants and their generic counterparts in secondary outcomes varied across different drugs.ConclusionsCompared to most generic antidepressants, brand-name drugs exhibited more protective effects on psychiatric hospitalization for depressive patients. These findings could serve as an important reference for clinicians when encountering patients with depressive disorder. 相似文献
30.